Лучшие больницы для «Osteoporosis Treatment» в Мумбаи, Индия

Osteoporosis is defined by the World Health Organization as a bone mineral density (BMD) T-score of −2.5 or below at the femoral neck, total hip, or lumbar spine as measured by dual-energy X-ray absorptiometry (DXA). The disease represents a fundamental imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation, resulting in a net loss of trabecular and cortical bone mass. Postmenopausal estrogen deficiency accelerates this process dramatically, as does prolonged glucocorticoid therapy, male hypogonadism, malabsorption syndromes, chronic kidney disease, and hyperthyroidism. Secondary osteoporosis accounts for approximately 30% of cases in women and up to 55% in men, underscoring the importance of thorough etiological workup before initiating therapy.

• Postmenopausal women aged 50 and above with a DXA T-score of −2.5 or below at the hip or lumbar spine (osteoporosis), or T-score between −1.0 and −2.5 with a 10-year major osteoporotic fracture probability ≥20% by FRAX® (high-risk osteopenia)
• Men aged 50 and above with documented low BMD (T-score ≤−2.5) or prior fragility fracture, or those on long-term glucocorticoid therapy (≥7.5 mg prednisone equivalent per day for ≥3 months)
• Patients with a history of low-trauma (fragility) fracture at any site, regardless of measured BMD — including vertebral, hip, wrist, proximal humerus, or pelvis fractures occurring from a standing height or less
• Individuals with secondary causes of bone loss: chronic corticosteroid use, hypogonadism (including androgen deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer), malabsorption (celiac disease, inflammatory bowel disease, bariatric surgery), hyperthyroidism, hyperparathyroidism, or chronic kidney disease (CKD stage 3b and above)
• Patients who have failed, are intolerant to, or are contraindicated for first-line oral bisphosphonate therapy, who require transition to parenteral or anabolic agents
• +1 more

- DXA scan (lumbar spine L1–L4, total hip, femoral neck; with vertebral fracture assessment [VFA] if indicated)

- FRAX® 10-year fracture probability calculation (with or without BMD)

Osteoporosis management encompasses a spectrum from lifestyle optimization and nutritional correction through sophisticated pharmacotherapy to interventional and surgical procedures for fracture management. Treatment selection is individualized based on fracture risk category (high vs. very high), patient comorbidities, tolerability profile, and prior treatment history.

Pharmacotherapy — Anti-resorptive AGENTS:

• Oral Bisphosphonates (First-Line, Standard): Alendronate (70 mg weekly) and risedronate (35 mg weekly or 150 mg monthly) reduce vertebral fracture risk by 40–50% and hip fracture risk by 25–40% in RCT data. Must be taken fasting with plain water, upright posture maintained for 30 minutes. Drug holidays are considered after 5 years (alendronate) or 3 years (risedronate) based on ongoing fracture risk reassessment.
• Intravenous Zoledronic Acid (Zometa/Reclast, 5 mg annually): Preferred for patients unable to tolerate oral bisphosphonates, those with GI malabsorption, or requiring high-potency therapy. Reduces hip fracture risk by 41% and vertebral fractures by 70% in pivotal trials. Requires pre-hydration; acute-phase reaction (flu-like symptoms) occurs in ~30% after first infusion.
• Denosumab (Prolia, 60 mg SC every 6 months): A fully human monoclonal antibody targeting RANK Ligand (RANKL), inhibiting osteoclast maturation and activation. Reduces vertebral fracture risk by 68% and hip fracture risk by 40% (FREEDOM trial). Preferred in renal impairment (any eGFR), and appropriate for patients on aromatase inhibitors or androgen deprivation therapy. Critical caveat: Denosumab discontinuation without sequential bisphosphonate therapy results in rapid, rebound bone loss and multiple vertebral fractures — requiring expert transition planning.
• Selective Estrogen Receptor Modulators (SERMs): Raloxifene (60 mg daily) reduces vertebral fracture risk by 30–50% without endometrial or breast stimulation. Does not prevent hip fractures. Appropriate for younger postmenopausal women at high vertebral fracture risk with breast cancer risk concerns.
• Hormone Replacement Therapy (HRT/MHT): Estrogen-containing regimens preserve BMD and reduce fracture risk; considered in women aged under 60 or within 10 years of menopause when climacteric symptoms co-exist with bone loss risk.

Pharmacotherapy — Anabolic (bone-building) AGENTS:

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–3 Before Travel)

• Patient submits prior medical records, imaging (DXA reports, X-rays, MRI), blood tests, and fracture history to GAF Healthcare's clinical coordination team.
• GAF Healthcare's partner specialist (endocrinologist or rheumatologist) conducts a video teleconsultation, reviews FRAX® risk stratification, and proposes a customized treatment plan.
• GAF Healthcare arranges e-Medical Visa for India (typically approved within 3–5 business days) or UAE entry/visitor visa facilitation.
• Pre-travel checklist: Ensure current medications are documented, dental clearance obtained if anti-resorptive therapy is planned, and any prior contrast allergy documented for IV procedures.

PHASE 2 — ARRIVAL & COMPREHENSIVE WORKUP (Days 1–3 In-Country)